EPISODE · Oct 7, 2025 · 16 MIN
Soufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors
from BiotechTV - News · host BiotechTV
CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targets and design ligands that carry payloads to them such as siRNAs and ASOs. The company plans to be in the clinic next year and is starting out with muscle conditions.
Embed this episode
Ready to play
Soufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.